Lupin Unveils Generic Cancer Treatment Drug in US Market

Lupin, a Mumbai-based pharmaceutical company, has launched a generic cancer treatment drug, Doxorubicin Hydrochloride Liposome Injection, in the US market. The drug is a generic version of Baxter Healthcare's Doxil used for treating ovarian cancer, AIDS-related Kaposi’s Sarcoma, and multiple myeloma. The product's estimated annual sales in the US is USD 40.9 million.

Mumbai-based pharmaceutical company Lupin announced on Thursday the launch of its generic cancer treatment drug in the US market.

Lupin introduced Doxorubicin Hydrochloride Liposome Injection single-dose vials following approval from the USFDA, in partnership with ForDoz Pharma Corporation.

The drug is a generic version of Baxter Healthcare Corporation's Doxil, indicated for ovarian cancer, AIDS-related Kaposi's Sarcoma, and multiple myeloma.

According to Iqvia MATdata, the product's estimated annual sales in the US is USD 40.9 million. On Thursday, Lupin's shares closed at Rs 2,195.20, up 0.21% on the BSE.

(With inputs from agencies.)